NCT04578392 (SPARES) is a NA clinical trial of high ligation of ileocolic artery in Crohn Disease, sponsored by The Cleveland Clinic.

Who is sponsoring NCT04578392?

NCT04578392 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT04578392?

Interventions in NCT04578392: high ligation of ileocolic artery, mesenteric sparing.

What condition does NCT04578392 study?

NCT04578392 studies Crohn Disease.

Is NCT04578392 still recruiting?

NCT04578392 is currently terminated. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT04578392: SPARES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

Terminated NA Last updated 16 April 2026

What this trial tests

NA trial testing high ligation of ileocolic artery in Crohn Disease in 13 participants. Terminated before completion.

Timeline

28 July 2020

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	28 July 2020
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	7 locations across Italy, Canada, United States, United Kingdom

Drugs / interventions tested

high ligation of ileocolic artery
mesenteric sparing

Conditions studied

Crohn Disease — all drugs for Crohn Disease →

Sponsor

The Cleveland Clinic

Who can join

Adults 18 to 65, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary ileocecal resection. Study sites - Multicenter international study Description of study intervention - Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection Participate duration - 5 years

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Management of Post-Operative Crohn's Disease: Knowns and Unknowns.
Spertino M, Gabbiadini R, Dal Buono A, Busacca A, et al · · 2024 · cited 4× · PMID 38673573 · DOI 10.3390/jcm13082300
Intriguing Role of the Mesentery in Ileocolic Crohn's Disease.
Turri G, Carvello M, Ben David N, Spinelli A. · · 2022 · cited 3× · PMID 35966976 · DOI 10.1055/s-0042-1743590
To cut or not to cut? Extended mesenteric excision during intestinal resection does not impact the postoperative recurrence nor the postoperative complications in Crohn's disease: a systematic review and meta-analysis.
Topala M, Martinekova P, Rancz A, Veres DS, et al · · 2025 · cited 2× · PMID 40057619 · DOI 10.1007/s10151-025-03110-w
Effect of extensive mesenteric excision on primary ileocolic resection outcomes in Crohn's disease patients: a systematic review with meta-analysis.
Martínez-Pérez A, Schena CA, Pellino G, Martínez-López E, et al · · 2025 · PMID 41329358 · DOI 10.1007/s00384-025-05043-0

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04578392 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04578392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing